Inhibitors of Hepatitis C virus polymerase
US10947210B2 · kind B2 · utility
1Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2019 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Sep 25, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.